This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelly, B. P.
Right arrow Articles by Orme, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, B. P.
Right arrow Articles by Orme, I. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Dec 1996, 2809-2812, Vol 40, No. 12
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis

BP Kelly, SK Furney, MT Jessen and IM Orme
Department of Microbiology, Colorado State University, Fort Collins 80523, USA.

As a paradigm for chronic infectious diseases, tuberculosis exhibits a variety of clinical presentations, ranging from primary pulmonary tuberculosis to reactivation tuberculosis and cavitary disease. To date, the animal models used in evaluating chemotherapy of tuberculosis have been high-dose intravenous models that mimic the disseminated forms of the disease. In the present study, we have used a low-dose aerosol exposure model which we feel better reflects newly diagnosed tuberculosis in patients converting to tuberculin positivity. As appropriate examples of chemotherapy, four rifamycins (rifampin, rifabutin, rifapentine, and KRM-1648) were tested, first in an in vitro murine macrophage model and then in the low-dose aerosol infection model, for their activity against Mycobacterium tuberculosis. In both models, KRM-1648 had the highest level of activity of the four compounds. In the infected-lung model, rifabutin, rifapentine, and KRM- 1648 all had sterilizing activity when given orally at 5 mg/kg of body weight per day. When given at 2.5 mg/kg/day, KRM-1648 had the highest level of activity of the four drugs, reducing the bacterial load by 2.7 logs over 35 days of therapy.


This article has been cited by other articles:

  • Zhang, T., Zhang, M., Rosenthal, I. M., Grosset, J. H., Nuermberger, E. L. (2009). Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis Infection. Am. J. Respir. Crit. Care Med. 180: 1151-1157 [Abstract] [Full Text]  
  • Woolhiser, L. K., Hoff, D. R., Marietta, K. S., Orme, I. M., Lenaerts, A. J. (2009). Testing of Experimental Compounds in a Relapse Model of Tuberculosis Using Granulocyte-Macrophage Colony-Stimulating Factor Gene-Disrupted Mice. Antimicrob. Agents Chemother. 53: 306-308 [Abstract] [Full Text]  
  • Lenaerts, A. J., Bitting, C., Woolhiser, L., Gruppo, V., Marietta, K. S., Johnson, C. M., Orme, I. M. (2008). Evaluation of a 2-Pyridone, KRQ-10018, against Mycobacterium tuberculosis In Vitro and In Vivo. Antimicrob. Agents Chemother. 52: 1513-1515 [Abstract] [Full Text]  
  • Lewis, C. C., Yang, J. Y. H., Huang, X., Banerjee, S. K., Blackburn, M. R., Baluk, P., McDonald, D. M., Blackwell, T. S., Nagabhushanam, V., Peters, W., Voehringer, D., Erle, D. J. (2008). Disease-Specific Gene Expression Profiling in Multiple Models of Lung Disease. Am. J. Respir. Crit. Care Med. 177: 376-387 [Abstract] [Full Text]  
  • Talaat, A. M., Ward, S. K., Wu, C.-W., Rondon, E., Tavano, C., Bannantine, J. P., Lyons, R., Johnston, S. A. (2007). Mycobacterial Bacilli Are Metabolically Active during Chronic Tuberculosis in Murine Lungs: Insights from Genome-Wide Transcriptional Profiling. J. Bacteriol. 189: 4265-4274 [Abstract] [Full Text]  
  • Nikonenko, B. V., Protopopova, M., Samala, R., Einck, L., Nacy, C. A. (2007). Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs. Antimicrob. Agents Chemother. 51: 1563-1565 [Abstract] [Full Text]  
  • Protopopova, M., Hanrahan, C., Nikonenko, B., Samala, R., Chen, P., Gearhart, J., Einck, L., Nacy, C. A. (2005). Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 56: 968-974 [Abstract] [Full Text]  
  • Lenaerts, A. J., Gruppo, V., Marietta, K. S., Johnson, C. M., Driscoll, D. K., Tompkins, N. M., Rose, J. D., Reynolds, R. C., Orme, I. M. (2005). Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against Mycobacterium tuberculosis in a Series of In Vitro and In Vivo Models. Antimicrob. Agents Chemother. 49: 2294-2301 [Abstract] [Full Text]  
  • Nikonenko, B. V., Samala, R., Einck, L., Nacy, C. A. (2004). Rapid, Simple In Vivo Screen for New Drugs Active against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48: 4550-4555 [Abstract] [Full Text]  
  • Jayaram, R., Shandil, Radha. K., Gaonkar, S., Kaur, P., Suresh, B. L., Mahesh, B. N., Jayashree, R., Nandi, V., Bharath, S., Kantharaj, E., Balasubramanian, V. (2004). Isoniazid Pharmacokinetics-Pharmacodynamics in an Aerosol Infection Model of Tuberculosis. Antimicrob. Agents Chemother. 48: 2951-2957 [Abstract] [Full Text]  
  • Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., Bishai, W. R., Grosset, J. H. (2004). Paucibacillary Tuberculosis in Mice after Prior Aerosol Immunization with Mycobacterium bovis BCG. Infect. Immun. 72: 1065-1071 [Abstract] [Full Text]  
  • SCOTT, C. P., KUMAR, N., BISHAI, W. R., MANABE, Y. C. (2004). SHORT REPORT: MODULATION OF MYCOBACTERIUM TUBERCULOSIS INFECTION BY PLASMODIUM IN THE MURINE MODEL. Am J Trop Med Hyg 70: 144-148 [Abstract] [Full Text]  
  • Jayaram, R., Gaonkar, S., Kaur, P., Suresh, B. L., Mahesh, B. N., Jayashree, R., Nandi, V., Bharat, S., Shandil, R. K., Kantharaj, E., Balasubramanian, V. (2003). Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis. Antimicrob. Agents Chemother. 47: 2118-2124 [Abstract] [Full Text]  
  • Lenaerts, A. J. M., Gruppo, V., Brooks, J. V., Orme, I. M. (2003). Rapid In Vivo Screening of Experimental Drugs for Tuberculosis Using Gamma Interferon Gene-Disrupted Mice. Antimicrob. Agents Chemother. 47: 783-785 [Abstract] [Full Text]  
  • FATTORINI, L., CRETI, R., NISINI, R., PIETROBONO, R., FAN, Y., STRINGARO, A., ARANCIA, G., SERLUPI-CRESCENZI, O., IONA, E., OREFICI, G. (2002). Recombinant GroES in combination with CpG oligodeoxynucleotides protects mice against Mycobacterium avium infection. J Med Microbiol 51: 1071-1079 [Abstract] [Full Text]  
  • Tuberculosis Drug Screening Program, (2001). Search for New Drugs for Treatment of Tuberculosis. Antimicrob. Agents Chemother. 45: 1943-1946 [Full Text]  
  • Lenaerts, A. M., Chase, S. E., Cynamon, M. H. (2000). Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model. Antimicrob. Agents Chemother. 44: 3167-3168 [Abstract] [Full Text]  
  • Shoen, C. M., Chase, S. E., DeStefano, M. S., Harpster, T. S., Chmielewski, A. J., Cynamon, M. H. (2000). Evaluation of Rifalazil in Long-Term Treatment Regimens for Tuberculosis in Mice. Antimicrob. Agents Chemother. 44: 1458-1462 [Abstract] [Full Text]  
  • Lenaerts, A. M. J. A., Chase, S. E., Chmielewski, A. J., Cynamon, M. H. (1999). Evaluation of Rifapentine in Long-Term Treatment Regimens for Tuberculosis in Mice. Antimicrob. Agents Chemother. 43: 2356-2360 [Abstract] [Full Text]  
  • Brooks, J. V., Orme, I. M. (1998). Evaluation of Once-Weekly Therapy for Tuberculosis Using Isoniazid plus Rifamycins in the Mouse Aerosol Infection Model. Antimicrob. Agents Chemother. 42: 3047-3048 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»